Hematology, Oncology and Pathology Services, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Braz J Infect Dis. 2012 Jan-Feb;16(1):74-7. doi: 10.1016/s1413-8670(12)70278-7.
AIDS-related lymphomas (ARL) present high biological heterogeneity. For better characterization of this type of lymphoma, the objectives of the present study were to evaluate the expression of immunohistochemical markers of cell differentiation (CD10, Bcl-6, MUM-1) and determine cell origin profile according to Hans' classification of diffuse large B-cell lymphoma in AIDS patients. This study included 72 consecutive patients with ARL diagnosed at the University Hospital, Universidade Federal do Rio de Janeiro (UFRJ) and at the Brazilian Instituto Nacional de Câncer (INCA) from 2000 to 2006. The morphologic distribution of the lymphomas was the following: 61% were diffuse large B-cell lymphomas (DLBCLs), 15% were Burkitt's lymphomas, 13% were plasmablastic lymphomas, 10% were high-grade lymphomas and 1% was follicular lymphoma. The positivity for each immunohistochemical marker in DLBCLs, Burkitt's lymphoma and plasmablastic lymphoma was respectively: CD20, 84%, 100%, and 0; CD10, 55%, 100%, and 0; Bcl-6, 45%, 80%, and 0; MUM-1, 41%, 20%, and 88%. A higher positivity of CD20 (84% x 56%, p = 0.01) was found in DLBCL compared to non-DLBCL; in Burkitt's lymphomas a higher positivity of CD10 (100% x 49%, p = 0.04) and Bcl-6 (80% x 39%, p = 0.035) were found compared to non-Burkitt's lymphomas. Germinal center (GC) profile was detected in 60% of DLBCLs. Our study suggests particular findings in ARL, as the most frequent phenotype was GC, different from HIV-negative patients.
艾滋病相关淋巴瘤（ARL）具有高度的生物学异质性。为了更好地描述这种类型的淋巴瘤，本研究的目的是评估细胞分化的免疫组织化学标志物（CD10、Bcl-6、MUM-1）的表达，并根据艾滋病患者弥漫性大 B 细胞淋巴瘤 Hans 分类确定细胞起源谱。本研究纳入了 2000 年至 2006 年在里约热内卢联邦大学医院（UFRJ）和巴西国家癌症研究所（INCA）连续诊断为 ARL 的 72 例患者。淋巴瘤的形态分布如下：61%为弥漫性大 B 细胞淋巴瘤（DLBCL），15%为伯基特淋巴瘤，13%为浆母细胞淋巴瘤，10%为高级别淋巴瘤，1%为滤泡性淋巴瘤。在 DLBCL、伯基特淋巴瘤和浆母细胞淋巴瘤中，每个免疫组织化学标志物的阳性率分别为：CD20，84%、100%和 0；CD10，55%、100%和 0；Bcl-6，45%、80%和 0；MUM-1，41%、20%和 88%。与非 DLBCL 相比，DLBCL 中 CD20 的阳性率更高（84%x56%，p=0.01）；伯基特淋巴瘤中 CD10（100%x49%，p=0.04）和 Bcl-6（80%x39%，p=0.035）的阳性率更高。60%的 DLBCL 中检测到生发中心（GC）表型。本研究表明 ARL 具有特殊的发现，最常见的表型为 GC，与 HIV 阴性患者不同。
